dc.creator | Tsolaki V., Karvouniaris M., Manoulakas E., Kotlia P., Karadontas V., Fotakopoulos G., Zakynthinos E., Makris D. | en |
dc.date.accessioned | 2023-01-31T10:17:04Z | |
dc.date.available | 2023-01-31T10:17:04Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.1016/j.jcrc.2018.07.025 | |
dc.identifier.issn | 08839441 | |
dc.identifier.uri | http://hdl.handle.net/11615/80077 | |
dc.description.abstract | “Healthcare-associated ventriculitis and meningitis” is a potentially devastating illness following neurosurgical procedures. Multidrug resistant (MDR) and extensively drug resistant (XDR) organisms such as Acinetobacter baumannii and Klebsiella pneumoniae have increasingly been isolated in ventriculitis and meningitis episodes. The treatment of these infections can be challenging, as the antimicrobial options are restricted. Regarding Central Nervous System (CNS) infections the transfer of the antibiotics to the Cerebrospinal Fluid (CSF) is often low which results in decreased drug levels at the infection site. The intraventricular (IVT) administration of antibiotics can be used as an adjunct to the intravenous (IV) treatment of Gram-negative MDR ventriculitis and meningitis, yet pertinent data is scarce. We present the successful management of three cases of healthcare-associated ventriculitis and meningitis due to XDR species with the combined intraventricular administration of colistin and off-label tigecycline, after the initial regimen of colistin given alone through both IVT and IV routes had failed. © 2018 Elsevier Inc. | en |
dc.language.iso | en | en |
dc.source | Journal of Critical Care | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053351697&doi=10.1016%2fj.jcrc.2018.07.025&partnerID=40&md5=7c9577f92f1132a83b9e4e1b230a656c | |
dc.subject | amikacin | en |
dc.subject | colistin | en |
dc.subject | glucose | en |
dc.subject | meropenem | en |
dc.subject | tigecycline | en |
dc.subject | tobramycin | en |
dc.subject | antiinfective agent | en |
dc.subject | colistin | en |
dc.subject | tigecycline | en |
dc.subject | Acinetobacter baumannii | en |
dc.subject | adult | en |
dc.subject | antibiotic sensitivity | en |
dc.subject | brain ventriculitis | en |
dc.subject | case report | en |
dc.subject | case study | en |
dc.subject | cerebellum hemorrhage | en |
dc.subject | cerebrospinal fluid analysis | en |
dc.subject | cerebrospinal fluid culture | en |
dc.subject | cerebrospinal fluid glucose level | en |
dc.subject | cerebrospinal fluid level | en |
dc.subject | clinical article | en |
dc.subject | disease association | en |
dc.subject | excision | en |
dc.subject | female | en |
dc.subject | fever | en |
dc.subject | hospital admission | en |
dc.subject | human | en |
dc.subject | intensive care unit | en |
dc.subject | Klebsiella pneumoniae | en |
dc.subject | Letter | en |
dc.subject | male | en |
dc.subject | meningitis | en |
dc.subject | middle aged | en |
dc.subject | minimum inhibitory concentration | en |
dc.subject | nonhuman | en |
dc.subject | pleocytosis | en |
dc.subject | postoperative period | en |
dc.subject | septic shock | en |
dc.subject | treatment duration | en |
dc.subject | treatment outcome | en |
dc.subject | ventriculostomy | en |
dc.subject | Acinetobacter infection | en |
dc.subject | brain ventriculitis | en |
dc.subject | central nervous system | en |
dc.subject | combination drug therapy | en |
dc.subject | drug effect | en |
dc.subject | encephalitis | en |
dc.subject | intracerebroventricular drug administration | en |
dc.subject | intravenous drug administration | en |
dc.subject | Klebsiella infection | en |
dc.subject | methodology | en |
dc.subject | multidrug resistance | en |
dc.subject | young adult | en |
dc.subject | Acinetobacter baumannii | en |
dc.subject | Acinetobacter Infections | en |
dc.subject | Administration, Intravenous | en |
dc.subject | Anti-Bacterial Agents | en |
dc.subject | Central Nervous System | en |
dc.subject | Cerebral Ventriculitis | en |
dc.subject | Colistin | en |
dc.subject | Drug Resistance, Multiple, Bacterial | en |
dc.subject | Drug Therapy, Combination | en |
dc.subject | Encephalitis | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Infusions, Intraventricular | en |
dc.subject | Injections, Intraventricular | en |
dc.subject | Klebsiella Infections | en |
dc.subject | Klebsiella pneumoniae | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Research Design | en |
dc.subject | Tigecycline | en |
dc.subject | Young Adult | en |
dc.subject | W.B. Saunders | en |
dc.title | Intraventricular CNS treatment with Colistin-Tigecycline combination: A case series | en |
dc.type | other | en |